By performing gain-of-function and loss-of-function studies in vitro and in vivo, we demonstrated that RASAL2 could suppress RCC angiogenesis by downregulation of VEGFA, which was critical for RCC progression and metastasis. This evidence concerns the gene RASAL2 and renal cell carcinoma.